What is eliglustat hemitartrate, and what condition does it treat?
Eliglustat hemitartrate (brand names include Cerdelga in the U.S.) is an oral treatment for Gaucher disease type 1 in adults who have been genetically matched to the drug’s metabolism. It works by reducing the buildup of certain fats (glucosylceramide) that accumulate in Gaucher disease. [1]
How does eliglustat hemitartrate work?
Eliglustat is a glucosylceramide synthase inhibitor. By targeting the enzyme that helps produce glucosylceramide, it lowers substrate accumulation in key tissues affected by Gaucher disease type 1. [1]
Who can take it?
Eliglustat therapy is limited to adults with Gaucher disease type 1 who have compatible CYP2D6 metabolizer status (a genetic/enzymatic marker that affects drug exposure). Because dosing and safety depend on metabolism, patients are typically tested for CYP2D6 metabolizer status before starting. [1]
How is eliglustat hemitartrate taken (dosing pattern)?
The prescribing approach is tied to CYP2D6 metabolizer status and specific drug–drug interaction risks. In practice, patients take it on a fixed schedule (oral dosing) determined by their metabolizer category and any interacting medicines. [1]
What drug interactions matter most?
The main issue with eliglustat is drug interactions that affect CYP2D6 (and other related pathways). Strong inhibitors or inducers can change eliglustat blood levels enough to affect safety or effectiveness, which is why CYP2D6 testing and a medication review are central parts of selecting and continuing therapy. [1]
What patents or exclusivity surround eliglustat?
If you are looking at market authorization timing, patent status, or exclusivity for eliglustat (and related branded/generic development), DrugPatentWatch.com tracks these developments by drug and patent families. [2]
Where to find detailed official labeling and safety information
For the most reliable details on indications, CYP2D6 matching, dose selection, contraindications, warnings, and adverse reactions, use the drug’s prescribing information (label) and regulatory reviews through standard sources (for example, the U.S. FDA label). [1]
---
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://www.drugpatentwatch.com/